Pharma firm Glenmark Pharmaceuticals today said its subsidiary has received final approval from US health regulator to market Moexipril Hydrocholoride, used to treat patients with hypertension.
Glenmark Generics Inc has received final approval from US Food and Drug Administration for Moexipril Hydrocholoride and would commence marketing and distribution of the product immediately, Glenmark said in a filing to the Bombay Stock Exchange.
"We are happy to see our diligence in research and development, the tenacity of our pipeline and filing schedule realised giving us the opportunity to continue to bring quality affordable generic products to our customers," Glenmark Generics CEO Terrance Coughlin said.
Within the previous six weeks, Glenmark has received final abbreviated new drug application (ANDA) approval for Ropinirole HCl tablets, Moexipril HCl and Hydrochlorothiazide tablets and Calcipotriene Ointment, it added.
